Surgical Endoscopy And Other Interventional Techniques

, Volume 20, Issue 3, pp 537–537

Alvimopan, a perpherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery

Results of a randomized, double-blind, controlled study

Authors

  • E. R. Viscusi
    • Jefferson Medical CollegeThomas Jefferson University
  • S. Goldstein
    • Jefferson Medical CollegeThomas Jefferson University
  • T. Witkowski
    • Jefferson Medical CollegeThomas Jefferson University
  • A. Andonakakis
    • Jefferson Medical CollegeThomas Jefferson University
  • R. Jan
    • Jefferson Medical CollegeThomas Jefferson University
  • K. Gabriel
    • Jefferson Medical CollegeThomas Jefferson University
  • W. Du
    • Adolor CorporationExton
  • L. Techner
    • Adolor CorporationExton
  • B. Wallin
    • Adolor CorporationExton
Erratum

DOI: 10.1007/s00464-006-3025-5

Cite this article as:
Viscusi, E., Goldstein, S., Witkowski, T. et al. Surg Endosc (2006) 20: 537. doi:10.1007/s00464-006-3025-5

[Surg Endosc (2006) 20: 64–70, DOI: 10.1007/s00464-005-0104-y]

On page 65, in column 1 of the “Patients and methods” section, the wrong study number was published. The first sentence under the heading “Study design and treatments” should read:

This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.

Copyright information

© Springer Science+Business Media, Inc. 2006